NCT04049630View on ClinicalTrials.gov

Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

January 16, 2021

Primary Completion Date

April 24, 2021

Study Completion Date

July 15, 2021

Conditions
Onchocerciasis, OcularLoiasis
Interventions
DRUG

LEV 1 mg/kg

A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.

DRUG

LEV 1,5 mg/kg

A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.

DRUG

LEV 2,5 mg/kg

A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.

DRUG

Placebo

5 tablets of placebo will be administrated to the participants.

Trial Locations (1)

Unknown

Secteur opérationnelle de la Santé, Ministère de la Santé et de la Population, Sibiti

All Listed Sponsors
lead

Programme National de Lutte contre l'Onchocercose, Republic of the Congo

OTHER_GOV

NCT04049630 - Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients | Biotech Hunter | Biotech Hunter